Macclesfield biotech Bivictrix Therapeutics raises £2.2m for cancer therapies

An estimated £2.2m in new capital has been raised by Bivictrix Therapeutics Limited in its latest funding round. The Macclesfield-based company operates within the sector of research and experimental development on biotechnology, focusing on next-generation multispecific antibody-drug conjugates. These therapies, also referred to as ADCs, are designed to be highly cancer-selective for the treatment of haematological malignancies and solid tumours.

The business was incorporated in 2021 and utilizes its proprietary Bi-Cygni platform to develop its product pipeline.

This investment follows the firm's financial activity in 2025, when it secured a total of £580.4k. Documentation for the current funding was filed in September 2026 (with the allotment date also occurring in the same month).